What's New

Ferring’s Propess® is the first pharmacological treatment for cervical ripening to be approved in Japan for over 20 years

  • Ferring announces that the Minister of Health, Labour and Welfare (MHLW) in Japan has approved Propess® (dinoprostone) for the initiation of cervical ripening1
  • Propess, developed in Scotland, UK, and marketed in over 60 countries, was approved following close collaboration with the patient community in Japan
  • This approval provides women in Japan with greater choice and is part of Ferring’s commitment to advancing Reproductive Medicine and Maternal Health worldwide

Saint-Prex, Switzerland – 23rd January, 2020 – Ferring Pharmaceuticals today announced that Propess® (dinoprostone) has been approved by the Minister of Health, Labour and Welfare (MHLW) in Japan for initiation of cervical ripening in patients at term (from 37 completed weeks of gestation).1 This is the first time in over 20 years that a pharmacological therapy for cervical ripening has been approved in the country.2

Around 10 per cent of births globally require induction of labour, which may be required if the health of the mother or baby is at risk.3,4 Cervical ripening is carried out prior to induction to prepare the cervix for birth. This approval offers women requiring an induction in Japan greater choice of alternatives to mechanical methods of cervical ripening.

“The approval of Propess in Japan is a big step forward in offering women more choice when it comes to cervical ripening,” said Per Falk, President and Chief Science Officer, Ferring Pharmaceuticals. “There is a lack of research and development of treatment options for women who are pregnant or giving birth, which is why it is important for Ferring to continue to invest and advance the field of Reproductive Medicine and Maternal Health and continue with our purpose of building families worldwide.”

The announcement today follows a close collaboration between Ferring Pharmaceuticals and a local patient advocacy group to ensure the needs and safety of women in labour are addressed in Japan.

“For women giving birth, mechanical methods may not always be the right option and it is important that a woman’s safety and comfort is paramount,” said Mikiya Kitamura, Vice President, Ferring Japan R&D. “Ensuring that a treatment is safe and effective is a priority for us, and we are pleased to have been able to work together with our local patient advocacy group on this significant milestone.”

Propess is currently marketed in over 60 countries and was developed in the 1980s in Scotland where it continues to be manufactured. As leaders in Reproductive Medicine and Maternal Health, this approval demonstrates Ferring’s continued commitment to helping people around the world to build healthy families.

About Propess5

Propess is a vaginal delivery system containing the active substance dinoprostone 10 mg used for the initiation of cervical ripening in women at term (from 37 completed weeks of gestation). The dinoprostone softens and opens the part of the birth canal known as the cervix, to start the process of labour.

About labour6

Labour is initiated or induced by obstetricians in situations where it is considered safer, for the mother or the unborn child, to be delivered. This could be due to pre-eclampsia (sudden, severe rise in blood pressure and kidney impairment), poor growth in the baby, unexplained bleeding in the last phase of pregnancy or a prolonged pregnancy (the most common reason). The success of induction of labour is related to the condition of the cervix prior to the induction. If during examination of the cervix length, positioning and softening, it is deemed unfavourable, then cervical ripening will be initiated.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build healthy families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

For more information, please contact

Bhavin Vaid

Head of Corporate Communications

+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)


Lindsey Rodger

Senior Manager, Corporate Communications

+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)